Your browser is no longer supported. Please, upgrade your browser.
Settings
REGN [NASD]
Regeneron Pharmaceuticals, Inc.
IndexS&P 500 P/E147.06 EPS (ttm)3.07 Insider Own1.20% Shs Outstand102.62M Perf Week-4.70%
Market Cap46.33B Forward P/E35.68 EPS next Y12.66 Insider Trans-22.78% Shs Float75.66M Perf Month7.90%
Income348.10M PEG7.80 EPS next Q2.69 Inst Own72.70% Short Float6.13% Perf Quarter9.09%
Sales2.82B P/S16.43 EPS this Y-19.40% Inst Trans0.82% Short Ratio5.20 Perf Half Y27.19%
Book/sh25.05 P/B18.02 EPS next Y16.10% ROA9.70% Target Price450.26 Perf Year50.35%
Cash/sh8.78 P/C51.45 EPS next 5Y18.86% ROE14.40% 52W Range269.50 - 495.50 Perf YTD10.05%
Dividend- P/FCF112.95 EPS past 5Y41.20% ROI12.20% 52W High-8.88% Beta0.85
Dividend %- Quick Ratio3.20 Sales past 5Y49.40% Gross Margin92.70% 52W Low67.53% ATR13.33
Employees2925 Current Ratio3.30 Sales Q/Q31.40% Oper. Margin29.70% RSI (14)52.76 Volatility3.50% 2.91%
OptionableYes Debt/Eq0.22 EPS Q/Q-1.00% Profit Margin12.30% Rel Volume0.99 Prev Close459.78
ShortableYes LT Debt/Eq0.18 EarningsFeb 10 BMO Payout0.00% Avg Volume891.05K Price451.48
Recom1.90 SMA200.99% SMA505.79% SMA20019.59% Volume884,505 Change-1.81%
Mar-27-15Reiterated Argus Buy $450 → $500
Mar-20-15Initiated Chardan Capital Markets Buy $560
Feb-19-15Downgrade ROTH Capital Buy → Neutral $461
Feb-17-15Reiterated Argus Buy $430 → $450
Feb-11-15Reiterated UBS Neutral $417 → $412
Feb-11-15Reiterated RBC Capital Mkts Outperform $480 → $490
Feb-02-15Reiterated RBC Capital Mkts Outperform $477 → $480
Nov-20-14Reiterated Brean Capital Buy $390 → $450
Nov-19-14Reiterated ROTH Capital Buy $422 → $461
Nov-11-14Reiterated Argus Buy $375 → $430
Nov-05-14Reiterated RBC Capital Mkts Outperform $373 → $410
Oct-24-14Reiterated Canaccord Genuity Buy $350 → $460
Sep-02-14Reiterated Brean Capital Buy $380 → $390
Aug-06-14Reiterated RBC Capital Mkts Outperform $349 → $373
Jul-21-14Initiated Argus Buy $375
Apr-16-14Initiated Canaccord Genuity Buy $350
Feb-13-14Downgrade Oppenheimer Outperform → Perform $310 → $325
Sep-30-13Reiterated Oppenheimer Outperform $300 → $310
Aug-22-13Initiated Oppenheimer Outperform $300
May-17-13Initiated UBS Neutral $290
Mar-30-15 06:55PM  Cramer: The best places for you to put new money at CNBC
03:50PM  Ohr Pharmaceutical Crashes on Disappointing Eye Drug Data - Analyst Blog
10:25AM  Why Citigroup Removed Gilead Sciences From Its 'Most Preferred' List at Barrons.com
Mar-27-15 07:23PM  Cramer Remix: A bottom in biotech? Hardly at CNBC
06:40PM  Cramer: 4 horsemen of biotech & semis are back at CNBC
04:20PM  Stocks Finish Lower for the Week as Fed Talk Spooks Investors at TheStreet
12:37PM  11 promising drugs poised to be the next billion-dollar blockbusters
Mar-26-15 04:14PM  Regeneron's Eylea Gets FDA Approval for Label Expansion - Analyst Blog
02:47PM  Is The Biotech Stock Correction A Buying Opportunity Or A Wake Up Call? at Forbes
02:12PM  Biotech Battering Renews Bubble Debate Over Sector's Pricey Stocks at Forbes
10:21AM  Biotech Crash -- How Long Will It Last? at Forbes
10:10AM  Stock Market News for March 26, 2015 - Market News
Mar-25-15 11:57PM  Dow tumbles 292 points as economy shows cracks at CNNMoney.com
08:13PM  Jim Cramer's 'Mad Money' Recap: This Market Has Gotten Too Hot at TheStreet
06:00PM  Cramer: Nasdaq's griddle too hot
03:11PM  In A Genetic Portrait Of A Nation, A Map Of The Future at Forbes
02:46PM  Biotechs On Track For Worst Week In A Year at Investor's Business Daily
12:09PM  U.S. FDA again expands usage of Regeneron eye drug Eylea Reuters
11:43AM  EYLEA┬« (aflibercept) Injection Receives FDA Approval for the Treatment of Diabetic Retinopathy in Patients with Diabetic Macular Edema (DME) at noodls
11:10AM  4 Top-Ranked Health Care ETFs for a Healthy Portfolio - ETF News And Commentary
11:02AM  EYLEA┬« (aflibercept) Injection Receives FDA Approval for the Treatment of Diabetic Retinopathy in Patients with Diabetic Macular Edema (DME) PR Newswire
10:28AM  Biotech Stock Roundup: Biogen Soars on Alzheimer's Data, Gilead HCV Drugs Label Update - Analyst Blog
Mar-24-15 07:33PM  Lightning Round: Problem with Visa's split at CNBC
Mar-23-15 01:30PM  Barrons 400 Index, ETF Make Some Changes ETF Trends
10:48AM  Pfizer, Lilly to resume study testing pain drug Reuters
07:00AM  Actavis' Wide-Moat Transformation Offers Shareholder Rewards at Morningstar
06:10AM  REGENERON PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Fi
12:00AM  Bristol, Sanofi and Novartis drugs to shine among 2015 launches Reuters
Mar-21-15 02:21PM  Don't-Buy Call on Biotech; Oil Pipeline: Jim Cramer's Best Blogs
Mar-20-15 07:26PM  Cramer Remix: Cha-ching! Time to cash in at CNBC
06:25PM  Cramer's don't buy call: REGN & BIIB
04:42PM  Regeneron Stops Paying CEOs Club Membership Dues, Filing Shows at Bloomberg
04:32PM  Give Gilead Credit for Surge in Biotech Margins at Barrons.com
03:21PM  Fore! Regeneron CEO Must Pay for his Own Golf Club Membership at The Wall Street Journal
01:01PM  Booming biotech stocks: REGN, CELG & more
09:26AM  New Cholesterol Meds May Lower Heart Risks, but Will They Break the Bank? at The Wall Street Journal
12:14AM  New Type of Cholesterol Drug Could Prove Costly at The Wall Street Journal
Mar-19-15 10:04PM  New Type of Cholesterol Drug Could Prove Costly at The Wall Street Journal
06:22PM  Cramer: Snap up this incredible opportunity at CNBC
11:52AM  Cramer -- Excitement in Biotech Continues, Retail Is 'All Over the Map' at TheStreet
09:30AM  The Zacks Analyst Blog Highlights: Amgen, Regeneron, Nektar, ACADIA and Pharmacyclics - Press Releases
Mar-18-15 07:34PM  Cramer Remix: Oil news you've been waiting for at CNBC
03:45PM  Investors Relieved? Akorn Stock Retakes 50-Day Line at Investor's Business Daily
02:47PM  Esperion Soars on Positive Phase IIb Data on ETC-1002 - Analyst Blog
02:32PM  Jim Cramer: Where Are the Regeneron (REGN) Profit-Takers? at TheStreet
10:50AM  Regeneron Hits a 52-Week High on Positive Praluent Data - Analyst Blog
10:49AM  Biotech Stock Roundup: Amgen & Regeneron Shine at ACC, Nektar Drug Disappoints - Analyst Blog
10:10AM  Stock Market News for March 18, 2015 - Market News
07:39AM  Remarkable Biotech Runs Continue
06:05AM  Cramer: Blame Market Malaise (Or Much of It) on the Strong U.S. Dollar at TheStreet
Mar-17-15 08:10PM  Akorn Leads 5 Drug Stocks Moving After Hours On News at Investor's Business Daily
11:39AM  Sanofi Upgraded On FX, Cholesterol Drug Promise at Investor's Business Daily
10:26AM  Esperion CEO Twitter Trolls His Larger, Cholesterol-Lowering Rivals at TheStreet
06:05AM  Jim Cramer on Biotech Stocks the Market Always Seems to Undervalue at TheStreet
06:00AM  Jim Cramer's Top Takeaways: Regeneron, Ulta Salon, Equinix at TheStreet
Mar-16-15 08:28PM  Top Stock Regeneron Breaks Out On Big Drug News at Investor's Business Daily +5.21%
06:17PM  Cramer: This sector has tons of hidden opportunity at CNBC
06:00PM  Cramer: Skepticism too thick
05:59PM  Regeneron/Sanofi's PCSK9 Drug Praluent Data Published - Analyst Blog
05:37PM  Amgen, Regeneron Stocks Go Up As Drugs Bring Cholesterol Down at Forbes
05:03PM  Amgen Presents Encouraging PCSK9 Inhibitor Repatha Data - Analyst Blog
03:17PM  Amgen, other drug company shares jump on cholesterol drug findings at MarketWatch
03:01PM  Amgen: Looking for a Wild Card at Barrons.com
02:51PM  Cardiology stocks with a pulse
01:44PM  New Cholesterol Drugs may Reduce Heart Risks, But Final Results Aren't In at The Wall Street Journal
11:04AM  Cramer: 'Remarkable' Data From Regeneron, Amgen; Sees Edward Lifesciences Going Higher at TheStreet
09:23AM  Cramer's Mad Dash: Regeneron breaking out
08:38AM  Prices of New Cholesterol Drugs Seen as Key for Amgen and Sanofi at Bloomberg
08:25AM  Will These Drugs Reduce Your Risk of Heart Disease? at Bloomberg
08:22AM  BUZZ-Sanofi: hits record high after good cholesterol drug data
08:00AM  Should You Be Worried About The Neurocognitive Side Effects Of The New Cholesterol Drugs? at Forbes
07:21AM  Heart drugs take center stage
06:09AM  REGENERON PHARMACEUTICALS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
01:24AM  PRESS DIGEST- New York Times business news - March 16 Reuters
12:10AM  [$$] New Cholesterol-Lowering Drugs May Cut Heart-Attack Risk at The Wall Street Journal
Mar-15-15 05:47PM  New Cholesterol-Lowering Drugs May Cut Heart-Attack Risk at The Wall Street Journal
11:20AM  Regeneron and Sanofi Announce 18-Month Results of ODYSSEY LONG TERM Trial with Praluent (alirocumab) Published in The New England Journal of Medicine at noodls
11:14AM  Sanofi, Regeneron: 18-Month Results of ODYSSEY LONG TERM Trial with Praluent(TM) (alirocumab) Published in The New England Journal of Medicine GlobeNewswire
11:00AM  These New Drugs Could Cut Heart Risks in Half
11:00AM  Sanofi and Regeneron Announce 18-Month Results of ODYSSEY LONG TERM Trial with Praluent (alirocumab) Published in The New England Journal of Medicine PR Newswire
11:00AM  Regeneron and Sanofi Announce 18-Month Results of ODYSSEY LONG TERM Trial with Praluent (alirocumab) Published in The New England Journal of Medicine PR Newswire
11:00AM  New Cholesterol Drugs: Highly Effective But Important Questions Remain at Forbes
11:00AM  New Cholesterol Drugs From Amgen, Sanofi Cut Heart Risks in Half at Bloomberg
11:00AM  Experimental cholesterol drugs cut heart risk, but questions remain
09:15AM  5 Stocks Investors Must Watch in the Week Ahead at 24/7 Wall St.
Mar-13-15 06:56PM  Cramer's Top 10 performers from the past 10 years at CNBC
06:11PM  Cramer's game plan: Biggest fear on the dollar at CNBC
06:00PM  CEOs to Cramer: We're going to win
03:33PM  These cholesterol drugs stocks are poised to move at CNBC
01:19PM  Watch these drug stocks Monday
11:27AM  Cramer: Regeneron's Cholesterol Drug Is Going to Be Really Big at TheStreet
09:52AM  Cramer's Stop Trading: Regeneron
08:46AM  These new meds could move stocks
Mar-12-15 08:07PM  Lightning Round: Good chance this is downgraded at CNBC
08:03PM  Cramer Remix: An Apple anniversary surprise at CNBC
07:00PM  Apple CEO Tim Cook surprises Jim
04:10PM  Bayer Seeks Eylea Label Expansion in the EU, Provides View - Analyst Blog
09:30AM  The Zacks Analyst Blog Highlights: AbbVie, Pharmacyclics, Amgen, United Therapeutics and Regeneron - Press Releases
12:59AM  Cramer's first CEO guest, 10 years later at CNBC
Mar-11-15 09:54AM  Biotech Stock Roundup: AbbVie to Buy Pharmacyclics, FDA Approves First Biosimilar - Analyst Blog
Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions worldwide. Its marketed products include EYLEA injection for the treatment of neovascular age-related macular degeneration (AMD) and macular edema; ZALTRAP, an injection for intravenous infusion for the treatment of patients with metastatic colorectal cancer; and ARCALYST, an injection for subcutaneous use for the treatment of cryopyrin-associated periodic syndromes comprising familial cold auto-inflammatory syndrome and muckle-wells syndrome in adults and children. The company's trap-based clinical product candidates comprise EYLEA for the treatment of AMD and diabetic macular edema; and ZALTRAP for oncology. Its antibody-based clinical programs include various human monoclonal antibody product candidates, such as REGN727 for low-density lipoprotein cholesterol reduction and for the prevention of cardiovascular events; REGN88 for rheumatoid arthritis and non-infectious uveitis; REGN668 for atopic dermatitis, asthma, nasal polyposis, and eosinophilic esophagitis; REGN2222 for respiratory syncytial virus; REGN1033 for skeletal muscle disorders; and REGN2176-3 and REGN910-3 antibodies for use in ophthalmology. The company is also developing REGN1908-1909, REGN1154, REGN1500, and REGN1193 antibody product candidates; REGN1400, REGN1979, and REGN2810 for oncology; and REGN475 for the treatment of pain. It has strategic collaboration with Sanofi to discover, develop, and commercialize human monoclonal antibodies; and license and collaboration agreement with Bayer HealthCare for the development and commercialization of EYLEA, as well as with Avalanche Biotechnologies, Inc. to discover, develop, and commercialize novel gene therapy products for the treatment of ophthalmologic diseases. The company was founded in 1988 and is headquartered in Tarrytown, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BAKER CHARLES ADirectorMar 25Option Exercise18.615,00093,05014,000Mar 26 04:20 PM
LAROSA JOSEPH JSVP General Counsel and SecretMar 25Option Exercise59.203,097183,34215,067Mar 26 04:21 PM
BAKER CHARLES ADirectorMar 25Sale454.965,0002,274,7859,000Mar 26 04:20 PM
Aberman Michael SSVP Strategy Investor RelationMar 24Sale478.994,8432,319,73812,498Mar 25 04:07 PM
Aberman Michael SSVP Strategy Investor RelationMar 18Sale465.003,4421,600,54222,498Mar 19 04:05 PM
Aberman Michael SSVP Strategy Investor RelationMar 17Option Exercise24.0011,398273,55229,998Mar 19 04:05 PM
Terifay Robert JSVP CommercialMar 17Sale451.0110,9934,957,90720,029Mar 18 06:03 PM
Terifay Robert JSVP CommercialMar 16Option Exercise30.6324,375746,60644,404Mar 18 06:03 PM
LAROSA JOSEPH JSVP General Counsel and SecretMar 16Option Exercise59.2020,2811,200,63528,311Mar 17 04:57 PM
LAROSA JOSEPH JSVP General Counsel and SecretMar 16Sale450.0018,3118,239,95010,000Mar 17 04:57 PM
McCorkle Douglas SVP Controller and Asst TreasurFeb 27Sale416.243,0001,248,7204,481Feb 27 04:31 PM
Tessier-Lavigne MarcDirectorFeb 26Option Exercise50.913,000152,7304,187Feb 27 04:32 PM
Tessier-Lavigne MarcDirectorFeb 26Sale421.953,0001,265,8641,187Feb 27 04:32 PM
Aberman Michael SSVP Strategy Investor RelationFeb 24Sale418.483,3741,411,95218,600Feb 25 04:02 PM
Terifay Robert JSVP CommercialFeb 24Sale423.6711,1734,733,66520,029Feb 25 04:01 PM
Aberman Michael SSVP Strategy Investor RelationFeb 23Option Exercise30.637,500229,72526,100Feb 25 04:02 PM
Terifay Robert JSVP CommercialFeb 23Option Exercise30.6324,375746,60644,404Feb 25 04:01 PM
Van Plew Daniel PSVP & General Mgr Industrial OFeb 23Sale427.829,4314,034,75418,705Feb 24 05:08 PM
Van Plew Daniel PSVP & General Mgr Industrial OFeb 20Option Exercise21.2520,000425,00038,705Feb 24 05:08 PM
RYAN ARTHUR FDirectorFeb 20Option Exercise125.7929,2503,679,49876,750Feb 23 04:06 PM
BROWN MICHAEL SDirectorFeb 20Option Exercise57.111,00057,1101,000Feb 23 04:07 PM
GOLDSTEIN JOSEPH LDirectorFeb 20Option Exercise177.825,000889,1009,000Feb 20 04:44 PM
GOLDSTEIN JOSEPH LDirectorFeb 20Sale423.655,0002,118,2624,000Feb 20 04:44 PM
RYAN ARTHUR FDirectorFeb 20Sale423.0129,25012,372,90847,500Feb 23 04:06 PM
BROWN MICHAEL SDirectorFeb 20Sale422.721,000422,7200Feb 23 04:07 PM
Aberman Michael SSVP Strategy Investor RelationFeb 17Sale404.463,6921,493,26618,600Feb 18 04:40 PM
Aberman Michael SSVP Strategy Investor RelationFeb 13Option Exercise24.007,500180,00026,100Feb 18 04:40 PM
SCHLEIFER LEONARD SPresident & CEOJan 02Sale410.581,500615,8670Jan 05 04:56 PM
Powchik PeterSVP Clinical Development & RegJan 02Sale414.0810,8224,481,21410,711Jan 05 04:28 PM
Powchik PeterSVP Clinical Development & RegDec 31Option Exercise52.0325,0001,300,75035,711Jan 05 04:28 PM
Powchik PeterSVP Clinical Development & RegDec 19Option Exercise30.633,26499,97610,711Dec 22 12:09 PM
Van Plew Daniel PSVP & General Mgr Industrial ODec 18Option Exercise30.633,26499,97618,705Dec 19 02:11 PM
McCorkle Douglas SVP Controller and Asst TreasurDec 17Option Exercise30.632,80085,7647,481Dec 18 04:22 PM
GOLDBERG MURRAY ASVP Administration & Asst SecrDec 16Option Exercise30.633,26499,97664,436Dec 18 04:25 PM
STAHL NEILSVP Research and Development SDec 16Option Exercise30.633,26499,9766,541Dec 18 04:25 PM
YANCOPOULOS GEORGEPresident Regeneron LaboratoriDec 16Option Exercise30.633,26499,976503,264Dec 18 04:23 PM
McCorkle Douglas SVP Controller and Asst TreasurDec 16Option Exercise49.076,818334,56010,556Dec 17 04:51 PM
McCorkle Douglas SVP Controller and Asst TreasurDec 16Sale410.006,8182,795,3804,681Dec 17 04:51 PM
McCorkle Douglas SVP Controller and Asst TreasurDec 15Option Exercise30.631,66851,0916,049Dec 17 04:51 PM
McCorkle Douglas SVP Controller and Asst TreasurDec 15Sale410.761,668685,1444,681Dec 17 04:51 PM
POON CHRISTINE ADirectorNov 25Buy410.00400164,000655Nov 26 01:28 PM
GILMAN ALFRED GDirectorNov 24Option Exercise35.9640,0001,438,55040,000Nov 25 04:16 PM
GILMAN ALFRED GDirectorNov 24Sale408.4440,00016,337,5850Nov 25 04:16 PM
STAHL NEILSVP Research and Development SNov 24Sale409.782,200901,5233,277Nov 24 04:15 PM
STAHL NEILSVP Research and Development SNov 21Sale415.163,1071,289,9025,477Nov 24 04:15 PM
STAHL NEILSVP Research and Development SNov 18Option Exercise115.2916,7571,931,91530,284Nov 20 04:14 PM
Terifay Robert JSVP CommercialNov 18Sale405.7922,3629,074,20020,029Nov 19 04:41 PM
Terifay Robert JSVP CommercialNov 17Option Exercise21.2548,7501,035,93868,779Nov 19 04:41 PM
Van Plew Daniel PSVP & General Mgr Industrial ONov 13Sale399.348,5753,424,33615,441Nov 14 04:32 PM
Van Plew Daniel PSVP & General Mgr Industrial ONov 12Option Exercise21.2518,700397,37534,141Nov 14 04:32 PM
GOLDSTEIN JOSEPH LDirectorNov 12Option Exercise177.825,000889,1009,000Nov 12 05:15 PM
GOLDSTEIN JOSEPH LDirectorNov 12Sale398.315,0001,991,5504,000Nov 12 05:15 PM
SCHLEIFER LEONARD SPresident & CEONov 12Sale400.3242,32416,943,28542,087Nov 12 05:14 PM
SCHLEIFER LEONARD SPresident & CEONov 11Sale400.003,4931,397,20084,411Nov 12 05:14 PM
SCHLEIFER LEONARD SPresident & CEOOct 31Sale400.113,4531,381,58087,904Nov 04 04:06 PM
SCHLEIFER LEONARD SPresident & CEOOct 28Sale404.0169,11227,921,80691,357Oct 29 04:27 PM
SCHLEIFER LEONARD SPresident & CEOOct 27Option Exercise19.40256,8084,982,219292,893Oct 29 04:27 PM
BROWN MICHAEL SDirectorOct 24Option Exercise57.115,000285,5505,000Oct 24 04:07 PM
BROWN MICHAEL SDirectorOct 24Sale399.005,0001,995,0000Oct 24 04:07 PM
GOLDBERG MURRAY ASVP Administration & Asst SecrOct 24Sale400.7026,78810,734,01863,102Oct 27 04:17 PM
GOLDBERG MURRAY ASVP Administration & Asst SecrOct 23Option Exercise30.6360,0001,837,800123,102Oct 27 04:17 PM
VAGELOS P ROYChairman of the BoardSep 10Sale350.0710,3263,614,82392,947Sep 10 04:00 PM
VAGELOS P ROYChairman of the BoardSep 08Sale351.002702103,273Sep 10 04:00 PM
YANCOPOULOS GEORGEPresident Regeneron LaboratoriAug 27Option Exercise314.315,7201,797,853505,720Aug 29 03:29 PM
McCorkle Douglas SVP Controller and Asst TreasurAug 27Option Exercise21.561,68136,2474,681Aug 28 02:39 PM
Tessier-Lavigne MarcDirectorAug 27Option Exercise50.913,000152,7304,187Aug 27 05:02 PM
Tessier-Lavigne MarcDirectorAug 27Sale352.203,0001,056,6001,187Aug 27 05:02 PM
GOLDSTEIN JOSEPH LDirectorAug 27Sale350.312,000700,6204,000Aug 27 05:01 PM
Tessier-Lavigne MarcDirectorAug 26Option Exercise50.911,38770,6121,387Aug 27 05:02 PM
Aberman Michael SVP Strategy and Investor RelatAug 22Option Exercise24.003,00072,00018,600Aug 26 09:45 AM
Aberman Michael SVP Strategy and Investor RelatAug 19Sale350.003,6111,263,85015,600Aug 19 04:16 PM
Aberman Michael SVP Strategy and Investor RelatAug 18Option Exercise52.038,750455,26324,350Aug 19 04:16 PM
McCorkle Douglas SVP Controller and Asst TreasurAug 18Option Exercise52.035,875305,6768,875Aug 18 04:04 PM
McCorkle Douglas SVP Controller and Asst TreasurAug 18Sale353.005,8752,073,8753,000Aug 18 04:04 PM
BROWN MICHAEL SDirectorAug 15Option Exercise33.423,000100,2603,000Aug 18 04:02 PM
BROWN MICHAEL SDirectorAug 15Sale349.203,0001,047,6000Aug 18 04:02 PM
GOLDSTEIN JOSEPH LDirectorAug 14Sale347.652,000695,3006,000Aug 14 04:14 PM
VAGELOS P ROYChairman of the BoardAug 13Sale340.018,0282,729,600248,540Aug 14 04:15 PM
STAHL NEILSVP Research and Development SAug 11Sale339.9611,6463,959,20413,527Aug 11 04:04 PM
VAGELOS P ROYChairman of the BoardAug 11Sale340.059,3723,186,967256,568Aug 11 05:25 PM
STAHL NEILSVP Research and Development SAug 08Sale340.642,100715,34025,173Aug 08 04:49 PM
VAGELOS P ROYChairman of the BoardAug 08Sale340.332,600884,858265,940Aug 11 05:25 PM
VAGELOS P ROYChairman of the BoardAug 07Option Exercise9.49270,3522,565,640411,191Aug 11 05:25 PM
STAHL NEILSVP Research and Development SAug 07Sale340.49741252,30427,273Aug 08 04:49 PM
STAHL NEILSVP Research and Development SAug 06Option Exercise21.2535,000743,75048,527Aug 08 04:49 PM
GOLDSTEIN JOSEPH LDirectorAug 06Sale331.202,000662,4008,000Aug 06 04:11 PM
REGENERON PHARMACEUTICALS INC10% OwnerAug 05Buy17.00588,2359,999,9951,809,098Aug 05 05:39 PM
Van Plew Daniel PSVP & General Mgr Industrial OMay 23Sale295.935,3691,588,87215,441May 23 03:58 PM
Van Plew Daniel PSVP & General Mgr Industrial OMay 22Option Exercise21.2511,200238,00026,641May 23 03:58 PM
POON CHRISTINE ADirectorMay 21Buy291.9025574,435255May 23 10:43 AM